Home › NDC Lookup › Ingredients › Triamcinolone Acetonide › 21922-0062-15
Triamcinolone Acetonide 1 mg/g Cream — NDC 21922-0062-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Triamcinolone Acetonide 1 mg/g Cream — NDC 21922-062-15 (Billing 21922-0062-15)

by Encube Ethicals, Inc. · 1 TUBE in 1 CARTON / 80 g in 1 TUBE

This is a package of Triamcinolone Acetonide 1 mg/g Cream from Encube Ethicals, Inc., marketed since Mar 2024 and currently FDA-listed; retail pharmacies pay about $0.0452 per g (NADAC).

NDC 21922-0062-15
🏷️ FDA NDC (as labeled) 21922-062-15 billing pads the product segment with a zero
This package
Contains80 g in 1 tube Cost per g$0.0452 NADAC Per package$3.62 / 80 g Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.1210/unit · Part D plans $0.1230/unit — full pricing hub ↓
Product page 21922-0062-05 Also comes in: 15 g 21922-062-04 30 g 21922-062-05 454 g 21922-062-30
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Aug 6, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 21922-062-15
Product NDC 21922-062
11-digit billing NDC 21922006215
NCPDP billing unit GM — per gram (weight)
RxCUI 1014314
UNII F446C597KA
UPC 0321922062052
Application # ANDA208848
SPL Set ID db87426f-124c-4ea9-bb15-fc3a0da10a4e
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-03-16
Route TOPICAL
Dosage form CREAM
Substance TRIAMCINOLONE ACETONIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 007594
GCN 31232
HICL code 002891
Ingredient (HICL) Triamcinolone Acetonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 48:10.08.00
AHFS class Corticosteroids (Respiratory Tract)
FDB label name TRIAMCINOLONE 0.1% CREAM
FDB brand name Triamcinolone Acetonide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007594
  • GCN: 31232
  • HICL (First Databank): 002891
  • AHFS class code: 48:10.08.00
  • RxCUI (RxNorm): 1014314
Why two NDCs? The FDA registers this code as 21922-062-15 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 21922-0062-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TRIAMCINOLONE 0.1% CREAM Ingredient Triamcinolone Acetonide
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Injections treat severe allergic conditions, joint inflammation, certain skin problems and eye inflammation. Creams and ointments calm itchy, inflamed sk...
  • Injections are given by a healthcare professional. Ointment is applied as a thin film to the affected area two to three times daily. Nasal spray bottles need priming before first u...
  • Possible effects include injection site pain, joint swelling, headache, muscle spasms, cough, sinusitis and bruising. People with diabetes may see higher blood sugar. Tell your doc...
  • Call right away for signs of an allergic reaction, fever or infection, a very painful and swollen joint, vision changes, or mood changes. Also report black stools, severe stomach p...
📖 Read our full Triamcinolone guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Triamcinolone Acetonide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.045 $3.62 / 80 g
Medicaid paysCMS SDUD · 12 mo $0.1210 $9.68 / 80 g
Medicare drug plans payPart D · Q2 2026 $0.1230 $9.84 / 80 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.052 $0.045
▼ Down 13% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
21922-0062-04 21922-062-04 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.1020 / g $1.53 2024-03-16 — Active
21922-0062-05 21922-062-05 Main listing 1 TUBE in 1 CARTON / 30 g in 1 TUBE $0.0822 / g $2.47 2024-03-16 — Active
21922-0062-15 You're viewing this 1 TUBE in 1 CARTON / 80 g in 1 TUBE $0.0452 / g $3.61 2024-03-16 — Active
21922-0062-30 21922-062-30 454 g in 1 JAR $0.0273 / g $12.39 2024-03-16 — Active

Per g, this pack runs about 66% above the cheapest pack (454 g, $0.0273 vs $0.0452 NADAC).

This pack accounts for about 26% of this product's recent Medicaid fills; the largest share goes to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 80 g in 1 tube.
What NDC number is used to bill for this package of Triamcinolone Acetonide 1 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide 1 mg/g 45802-0064-05 Padagis 454 g $0.027 AT Availability likely save 40%
Triamcinolone Acetonide 1 mg/g 45802-0055-05 Padagis 454 g $0.034 AT Availability likely save 25%
Triamcinolone Acetonide 1 mg/gthis 21922-0062-15 Encube 1 tube $0.045 AT Availability likely —
triamcinolone acetonide 1 mg/g 00168-0004-15 E. 1 tube $0.102 AT Availability likely +126%
Triamcinolone Acetonide 1 mg/g 00713-0225-15 Cosette 1 tube $0.102 AT Discontinued +126%
Triamcinolone Acetonide 1 mg/g 16714-0986-01 NorthStar 1 tube $0.102 AT Availability likely +126%
Triamcinolone Acetonide 1 mg/g 33342-0329-15 Macleods 1 tube $0.102 AT Availability likely +126%
Triamcinolone Acetonide 1 mg/g 51672-1282-01 Sun 1 tube $0.102 AT Availability likely +126%
Triamcinolone Acetonide 1 mg/g 67877-0251-15 Ascend 15 g $0.102 AT Availability likely +126%
Triamcinolone Acetonide 1 mg/g 71656-0042-15 Saptalis 1 tube $0.102 AT Availability likely +126%
Triamcinolone acetonide 1 mg/g 33342-0333-15 Macleods 1 tube $0.116 AT Availability likely +157%
Triamcinolone Acetonide 1 mg/g 51672-1284-01 Sun 1 tube $0.116 AT Availability likely +157%
Triamcinolone Acetonide 1 mg/g 00713-0228-15 Cosette 1 tube $0.116 AT Availability likely +157%
Triamcinolone acetonide 1 mg/g 16714-0276-01 NorthStar 1 tube $0.116 AT Availability likely +157%
Triamcinolone Acetonide 1 mg/g 21922-0063-04 Encube 1 tube $0.116 AT Availability likely +157%
Triamcinolone Acetonide 1 mg/g 00168-0006-15 E. 15 g $0.116 AT Availability likely +157%
Triamcinolone Acetonide 1 mg/g 64980-0320-05 Rising 1 tube $2.583 AT Availability likely +5621%
Triderm 1 mg/g 00316-0170-01 Crown 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-0162-00 A-S 80 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-0228-00 A-S 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-2106-00 A-S 30000 mg — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-6547-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-6566-00 A-S 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 52817-0811-15 TruPharma, 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0234-30 Direct_Rx 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0650-15 DIRECTRX 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63187-0025-15 Proficient 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63187-0053-15 Proficient 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63187-0870-15 Proficient 1 tube — — FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8778-01 Bryant 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8779-01 Bryant 30 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8780-01 Bryant 80 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8781-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63629-9573-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63629-9574-01 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 66267-0933-80 NuCare 80 g — — FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-2736-03 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3666-03 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3852-08 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3982-05 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4383-05 NuCare 15 g — — FDA listed —
triamcinolone acetonide 1 mg/g 68071-4391-03 NuCare 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4945-05 NuCare 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68462-0131-17 Glenmark 1 tube — — FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-7797-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8350-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8356-00 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8753-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-1524-00 REMEDYREPACK 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2285-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2403-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2963-00 REMEDYREPACK 1 tube — AT Discontinued —
Triamcinolone Acetonide 1 mg/g 70518-4527-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71205-0627-15 Proficient 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 71335-2211-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71335-2712-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71335-2713-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72162-1386-04 Bryant 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 72162-1832-03 Bryant 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0039-80 Direct_Rx 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0277-15 Direct_Rx 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0330-80 Direct 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0571-80 Direct_rx 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0670-30 Direct_rx 30 g — AT FDA listed —
Dermavyx 72835-0777-02 V2 1 kit — — FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0203-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0348-00 Asclemed 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0071-30 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0145-30 Proficient 1 tube — AT FDA listed —
Triadermex 84460-0100-08 Florrax 1 kit — — FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-2244-00 A-S 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-6978-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68462-0797-17 Glenmark 1 tube — — FDA listed —
Triamcinolone Acetonide 1 mg/g 71205-0108-15 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4286-05 NuCare 15 g — — FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-3508-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-1872-08 NuCare 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-3689-00 REMEDYREPACK 1 tube — AT FDA listed —
Kourzeq 1 mg/g 82682-0001-05 MidAmerica 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0361-00 Asclemed 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0079-30 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-4761-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-7679-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0619-15 DIRECTRX 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72162-2336-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 67296-1927-01 RedpharmDrug 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 68071-2362-05 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8386-05 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 85766-0244-15 Sportpharm 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 67296-2327-01 Redpharm 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Mar 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 8CRQ2TH63M
    Isopropyl palmitate is an oily liquid derived from palm oil. It acts as an emollient and lubricant in medicines, helping soften the skin or improve how the product spreads and flows.
  • UNII 33X04XA5AT
    Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
  • UNII 506T60A25R
    Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerEncube Ethicals, Inc.
Application holderENCUBE ETHICALS PRIVATE LTD
FDA applicationANDA208848 (ANDA)
Labeler code21922
First marketedMar 2024
Product typeHuman Prescription Drug
Portfolio77 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 22 words ▾

INDICATIONS AND USAGE Triamcinolone acetonide cream 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

⏱️ Dosage and Administration 188 words ▾

DOSAGE AND ADMINISTRATION Apply triamcinolone acetonide cream, 0.1% as appropriate, to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions.

Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication.

The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply triamcinolone acetonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day.

Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 80 words ▾

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS , contact Encube Ethicals Private Limited, at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

🤰 Pregnancy 94 words ▾

Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 114 words ▾

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 17 words ▾

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

🧬 Clinical Pharmacology 192 words ▾

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 114 words ▾

HOW SUPPLIED Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following: 15 g tube – NDC 21922-062-04 30 g tube – NDC 21922-062-05 80 g tube – NDC 21922-062-15 1 lb (454 g) jar – NDC 21922-062-30 Store at controlled room temperature 15°C to 30°C (59°F to 86°F). Avoid excessive heat. Protect from freezing.

Manufactured by: Encube Ethicals Pvt. Ltd. Plot No.

C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. OR Manufacture by: Encube Ethicals Pvt. Ltd.

Plot No. 113, Smart Industrial Park, Pithampur, District: Dhar – 454 774, Madhya Pradesh, India. Distributed by: Encube Ethicals, Inc.

200 Meredith Drive, Suite 202 Durham, NC 27713 USA Revised: 03/2025

📋 Description 92 words ▾

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone Acetonide Cream, USP contains Triamcinolone Acetonide [Pregna- 1,4- diene -3,20- dione,9-fluoro-11,21- dihydroxy-16,17- [(1- methylethylidene)bis-(oxy)]-, (11β,16α)-], with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50.

CAS 76-25-5. Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of triamcinolone acetonide per gram in a base containing emulsifying wax, cetyl alcohol, isopropyl palmitate, sorbitol solution, glycerin, lactic acid, benzyl alcohol and purified water. chemical structure

💬 Information for Patients 128 words ▾

Information for the Patient Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.

It is for external use only. Avoid contact with the eyes. 2.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.

Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis.

If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequencies of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique. Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity ( see PRECAUTIONS, Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. These preparations are not for ophthalmic use.

Information for the Patient Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.

It is for external use only. Avoid contact with the eyes. 2.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.

Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test; ACTH stimulation test. Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.

The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers It is not known whether topical administration of corticosteroids could result in suffici… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 58 words ▾

Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 38 words ▾

Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

📄 Package Label / Principal Display Panel ~2 min read ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 21922- 062 -04 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 15 grams Manufactured by: Encube Ethicals Pvt. Ltd. Plot No.

C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA NDC 21922- 062 -05 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 30 grams Manufactured by: Encube Ethicals Pvt.

Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India.

Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA NDC 21922- 062 -15 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 80 grams Manufactured by: Encube Ethicals Pvt. Ltd.

Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. Distributed by: Encube Ethicals, Inc.

200 Meredith Drive, Suite 202, Durham, NC 27713, USA NDC 21922- 062 -30 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 1 lb (454g) Manufactured by: Encube Ethicals Pvt. Ltd. Plot No.

C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA NDC 21922- 062 -04 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 15 grams Manufacture by: Encube Ethicals Pvt.

Ltd. Plot No. 113, Smart Industrial Park, Pithampur, District: Dhar – 454 774, Madhya Pradesh, India.

Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA NDC 21922- 062 -05 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 30 grams Manufacture by: Encube Ethicals Pvt. Ltd.

Plot No. 113, Smart Industrial Park, Pithampur, District: Dhar – 454 774, Madhya Pradesh, India. Distributed by: Encube Ethicals, Inc.

200 Meredith Drive, Suite 202, Durham, NC 27713, USA NDC 21922- 062 -15 Triamcinolone Acetonide Cream USP, 0.1 % For External Use Only Not For Ophthalmic Use Net Wt 80 grams Manufacture by: Encube Ethicals Pvt. Ltd. Plot No.

113, Smart Industrial Park, Pithampur, District: Dhar – 454 774, Madhya Pradesh, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA 15 gm carton label 30 gm carton label 80 gm carton label 454 gm carton label 15 cart 30 cart 80 cart

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
117.3K
Units reimbursed last 4 qtrs
9.6M
Gross reimbursed last 4 qtrs
$1.16M
Avg / prescription
$9.85
Avg / unit
$0.1210
Latest quarter Q1 2026
32.4KRx
Medicaid pays / g
$0.1210
gross reimbursed
vs
NADAC / g
$0.0452
acquisition cost
=
Spread
+$0.0758
+168% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
35% FFS 65% MCO
Fee-for-service · 40,791 Rx Managed care · 76,518 Rx
State Medicaid map
Alaska: 13,280 units · 1,812 per 100k residents AK Maine: 27,760 units · 1,990 per 100k residents ME Washington: 153,530 units · 1,965 per 100k residents WA Idaho: 55,127 units · 2,807 per 100k residents ID Montana: 20,365 units · 1,799 per 100k residents MT North Dakota: 13,120 units · 1,676 per 100k residents ND Minnesota: 188,510 units · 3,286 per 100k residents MN Wisconsin: 115,510 units · 1,954 per 100k residents WI Michigan: 298,949 units · 2,978 per 100k residents MI New York: 577,532 units · 2,951 per 100k residents NY Vermont: 9,040 units · 1,397 per 100k residents VT New Hampshire: 33,760 units · 2,408 per 100k residents NH Oregon: 134,685 units · 3,182 per 100k residents OR Nevada: 83,050 units · 2,600 per 100k residents NV Wyoming: 5,040 units · 863 per 100k residents WY South Dakota: 26,389 units · 2,871 per 100k residents SD Iowa: 67,578 units · 2,107 per 100k residents IA Illinois: 253,113 units · 2,017 per 100k residents IL Indiana: 188,490 units · 2,747 per 100k residents IN Ohio: 387,773 units · 3,290 per 100k residents OH Pennsylvania: 266,429 units · 2,056 per 100k residents PA New Jersey: 16,780 units · 181 per 100k residents NJ Massachusetts: 45,920 units · 656 per 100k residents MA California: 1,062,954 units · 2,728 per 100k residents CA Utah: 71,645 units · 2,097 per 100k residents UT Colorado: 123,450 units · 2,100 per 100k residents CO Nebraska: 34,940 units · 1,766 per 100k residents NE Missouri: 256,809 units · 4,145 per 100k residents MO Kentucky: 350,261 units · 7,739 per 100k residents KY West Virginia: 105,600 units · 5,966 per 100k residents WV Virginia: 199,185 units · 2,285 per 100k residents VA Maryland: 104,663 units · 1,694 per 100k residents MD Connecticut: 47,600 units · 1,316 per 100k residents CT Rhode Island: 8,800 units · 804 per 100k residents RI Arizona: 162,125 units · 2,182 per 100k residents AZ New Mexico: 86,300 units · 4,082 per 100k residents NM Kansas: 35,075 units · 1,193 per 100k residents KS Arkansas: 224,665 units · 7,325 per 100k residents AR Tennessee: 143,110 units · 2,008 per 100k residents TN North Carolina: 527,377 units · 4,867 per 100k residents NC South Carolina: 250,780 units · 4,667 per 100k residents SC Delaware: 15,314 units · 1,485 per 100k residents DE Oklahoma: 228,812 units · 5,645 per 100k residents OK Louisiana: 512,324 units · 11,201 per 100k residents LA Mississippi: 138,750 units · 4,719 per 100k residents MS Alabama: 127,664 units · 2,499 per 100k residents AL Georgia: 566,784 units · 5,139 per 100k residents GA D.C.: 9,894 units · 1,457 per 100k residents DC Hawaii: 10,565 units · 736 per 100k residents HI Texas: 552,474 units · 1,811 per 100k residents TX Florida: 593,608 units · 2,625 per 100k residents FL
Units reimbursed · per 100k residents
18111,201
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Louisiana 11,201 /100k
2 Kentucky 7,739 /100k
3 Arkansas 7,325 /100k
4 West Virginia 5,966 /100k
5 Oklahoma 5,645 /100k
6 Georgia 5,139 /100k
7 North Carolina 4,867 /100k
8 Mississippi 4,719 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube21922-0062-05 179,985 Rx · $1,759,716
1 tube21922-0062-04 146,913 Rx · $1,169,607
1 tube this page21922-0062-15 117,309 Rx · $1,155,813
454 g21922-0062-30 9,886 Rx · $211,459
Drug total (last 4 qtrs): 454,093 Rx · 24,943,400 units · $4,296,596 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 21922-0061-22 · Encube 21922-0063-04 · Encube →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.